Icatibant

Icatibant (trade name Firazyr) is a peptidomimetic drug consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by the European Commission for the symptomatic treatment of acute attacks, of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).